Target intelligence / Profile preview

PROX1 antisense RNA 1 (PROX1-AS1)

Target
PROX1-AS1
Molecular classification
Long non-coding RNA (lncRNA), Other (non-coding RNA family)
01

Overview

PROX1 antisense RNA 1 (PROX1-AS1) is a long non-coding RNA transcribed from the antisense strand of the PROX1 gene and located on human chromosome 1q32.3. It is not translated into protein. PROX1-AS1 is significantly upregulated in various cancers, including papillary thyroid carcinoma and gastric cancer, where it is implicated in promoting cell proliferation, migration, invasion, and suppression of apoptosis. Mechanistically, PROX1-AS1 can regulate tumor biology partly by acting as a competing endogenous RNA, sequestering tumor-suppressive microRNAs such as miR-877-5p and thereby altering expression of targets like PD-L1. In thyroid cancer, PROX1-AS1 has been shown to modulate the epithelial–mesenchymal transition, influencing metastatic potential. Due to these functions, PROX1-AS1 is an emerging biomarker and a potential therapeutic target in cancers, though no drugs act directly on it to date[1][2].

Other names
PROX1-AS1PROX1 antisense RNA 1 (non-protein coding)PROX1 antisense RNA 1
02

Mechanism of action

Indirect: Silencing or knockdown of PROX1-AS1 leads to inhibition of proliferation, migration, and invasion, and enhances apoptosis in cancer cells. Acts as a molecular sponge for specific microRNAs such as miR-877-5p, de-repressing downstream targets like PD-L1 in gastric cancer.

03

Biological functions

Regulation of cell proliferationRegulation of cell migrationRegulation of cell invasionModulation of apoptosisRegulation of epithelial–mesenchymal transition (EMT)Post-transcriptional regulation (as a competing endogenous RNA/ceRNA via miRNA sponging)
04

Disease associations

Cancer (notably papillary thyroid carcinoma, gastric cancer)Potential biomarker or risk factor in other malignancies and disease states
05

Safety considerations

No direct safety concerns or therapeutic challenges reported due to lack of clinical drugs targeting PROX1-AS1, but potential challenges include:Off-target effects of RNA-targeted therapeuticsLack of specificity in modulating non-coding RNAsNeed for safe and efficient delivery systems for RNA interference approaches
06

Interacting drugs

None identified as approved or in clinical use directly targeting PROX1-AS1 as of current knowledge
07

Biomarkers

PROX1-AS1 (expression level itself is a potential biomarker for cancer diagnosis or prognosis, particularly in papillary thyroid carcinoma and gastric cancer)Co-regulated molecules in the EMT pathway (E-cadherin, N-cadherin, Vimentin in thyroid cancer)MiR-877-5p and PD-L1 (in gastric cancer context)

Beyond the preview

Go deeper on PROX1 antisense RNA 1 (PROX1-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROX1 antisense RNA 1 (PROX1-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call